HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016

  • ID: 3788901
  • Report
  • 70 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • TGV-Laboratories
  • ViiV Healthcare Limited
  • MORE
HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016

Summary

‘HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016’, provides in depth analysis on HIV-1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.

The report provides comprehensive information on the HIV-1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for HIV-1 Integrase (EC 2.7.7.)
- The report reviews HIV-1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects
- The report assesses HIV-1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to HIV-1 Integrase (EC 2.7.7.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for HIV-1 Integrase (EC 2.7.7.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV-1 Integrase (EC 2.7.7.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • TGV-Laboratories
  • ViiV Healthcare Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

HIV-1 Integrase (EC 2.7.7.) Overview

Therapeutics Development

HIV-1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development

HIV-1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area

HIV-1 Integrase (EC 2.7.7.) - Products under Development by Indication

HIV-1 Integrase (EC 2.7.7.) - Pipeline Products Glance

Late Stage Products

Early Stage Products

HIV-1 Integrase (EC 2.7.7.) - Products under Development by Companies

HIV-1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes

HIV-1 Integrase (EC 2.7.7.) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

HIV-1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development

Critical Outcome Technologies Inc.

Gilead Sciences, Inc.

Merck & Co., Inc.

TGV-Laboratories

ViiV Healthcare Limited

HIV-1 Integrase (EC 2.7.7.) - Drug Profiles

(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabotegravir sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabotegravir sodium + rilpivirine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elvitegravir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-522 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-532 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2048 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HIV-1 Integrase for HIV infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Integrase for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-169 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV-1 Integrase (EC 2.7.7.) - Dormant Projects

HIV-1 Integrase (EC 2.7.7.) - Discontinued Products

HIV-1 Integrase (EC 2.7.7.) - Featured News & Press Releases

Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir

Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment

Jan 26, 2016: AHF Files Federal Lawsuit Against Gilead to Invalidate Patents on Key AIDS Drug

Dec 07, 2015: Health Canada Issues Notice of Compliance for Gilead's Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Nov 23, 2015: European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Nov 05, 2015: U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy

Oct 22, 2015: Gilead Announces Phase 3 Results for Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV

Sep 25, 2015: European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya for the Treatment of HIV

Jul 21, 2015: Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)

May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy

Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment

Feb 26, 2015: Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide

Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys

Nov 06, 2014: Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 70List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Critical Outcome Technologies Inc., H1 2016

Pipeline by Gilead Sciences, Inc., H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by TGV-Laboratories, H1 2016

Pipeline by ViiV Healthcare Limited, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 50List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • TGV-Laboratories
  • ViiV Healthcare Limited
  • MORE
According to our recently published report 'HIV-1 Integrase – Pipeline Review, H1 2016'; HIV-1 Integrase (EC 2.7.7.) pipeline Target constitutes close to 13 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; HIV-1 Integrase (EC 2.7.7.) HIV-1 integrase is a viral protein that catalyzes the first two steps of the three-step DNA integration process and belongs to the superfamily of polynucleotidyl transferases. The integration of HIV-1 DNA into the host chromosome is achieved by the integrase protein performing a series of DNA cleaving and ligation reactions.

The report 'HIV-1 Integrase – Pipeline Review, H1 2016' outlays comprehensive information on the HIV-1 Integrase (EC 2.7.7.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Critical Outcome Technologies Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
TGV-Laboratories
ViiV Healthcare Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll